Prognostic Significance of Left Axis Deviation in Acute Heart Failure Patients with Left Bundle branch block: an Analysis from the Korean Acute Heart Failure (KorAHF) Registry by 媛뺤꽍誘�
1002https://e-kcj.org
ABSTRACT
Background and Objectives: The prognostic impact of left axis deviation (LAD) on clinical 
outcomes in acute heart failure syndrome (AHFS) with left bundle branch block (LBBB) 
is unknown. The aim of this study was to determine the prognostic significance of axis 
deviation in acute heart failure patients with LBBB.
Methods: Between March 2011 and February 2014, 292 consecutive AHFS patients with LBBB 
were recruited from 10 tertiary university hospitals. They were divided into groups with no 
LAD (n=189) or with LAD (n=103) groups according to QRS axis <−30 degree. The primary 
outcome was all-cause mortality.
Results: The median follow-up duration was 24 months. On multivariate analysis, the rate of 
all-cause death did not significantly differ between the normal axis and LAD groups (39.7% 
vs. 46.6%, adjusted hazard ratio, 1.01; 95% confidence interval, 0.66, 1.53; p=0.97). However, 
on the multiple linear regression analysis to evaluate the predictors of the left ventricular 
ejection fraction (LVEF), presence of LAD significantly predicted a worse LVEF (adjusted 
beta, −3.25; 95% confidence interval, −5.82, −0.67; p=0.01). Right ventricle (RV) dilatation 
was defined as at least 2 of 3 electrocardiographic criteria (late R in lead aVR, low voltages in 
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limb leads, and R/S ratio <1 in lead V5) and was more frequent in the LAD group than in the 
normal axis group (p<0.001).
Conclusions: Among the AHFS with LBBB patients, LAD did not predict mortality, but it 
could be used as a significant predictor of worse LVEF and RV dilatation (Trial registry at 
KorAHF registry, ClinicalTrial.gov, NCT01389843).
Keywords: Bundle-branch block; Heart failure; Electrocardiography
INTRODUCTION
Left bundle branch block (LBBB) is a marker of poor prognosis in heart failure (HF) patients, 
and interest in LBBB is increasing due to the development of cardiac-resynchronization 
therapy (CRT).1-5) Among the randomized population included in the Multicenter Automatic 
Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) trial, 
LBBB patients without left axis deviation (LAD) appeared to receive a greater benefit from 
CRT than did those with LAD.6) The most common cause of LAD is left anterior fascicular 
block (LAFB), but LAFB cannot explain the LAD in patients with complete LBBB.7-9) The 
proposed mechanisms of LAD in patients with LBBB include attitudinal changes in the 
anatomy such as a cardiomegaly and changes in myocyte mass.10) A previous study showed 
that patients with LBBB with LAD had greater incidence of cardiomegaly, HF, advanced 
conduction disease, cardiovascular mortality, and major adverse cardiac event than those 
with a normal axis.11)12) Another study indicated that LBBB with LAD does not confer a 
significant mortality risk, but those with a normal axis who developed LAD during the study 
period had a significantly higher mortality.13) However, limited data is available regarding the 
prognostic significance of LAD in acute heart failure syndrome (AHFS) patients with LBBB. 
Therefore, the aim of the present study is to determine the association between LAD and the 
clinical outcomes of AHFS with LBBB.
METHODS
Study population
The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort. Between 
January 2011 and February 2014, a total of 5,625 patients, who were hospitalized due to AHFS 
were consecutively enrolled from 10 university hospitals. The patients are planned for follow-up 
until 2018. Patients who had signs or symptoms of HF and one of the following criteria were 
eligible for the study: 1) lung congestion or 2) objective findings of LV systolic dysfunction or 
structural heart disease. Lung congestion was defined as ‘congestion’ on a chest X-ray or as 
rales on physical examination. Electrocardiograms (ECGs) were recorded at a standard paper 
speed of 25 mm/s and calibration of 10 mm/mV. They were read by trained physicians who were 
blinded to clinical data, site interpretation, and patient outcomes. LBBB was defined by the 
following criteria: 1) QRS duration >120 ms, 2) broad notched or slurred R waves in leads I, aVL, 
V5, and V6, and an occasional RS pattern in V5 and V6 attributed to a displaced transition of the 
QRS complex, 3) absent Q waves in leads I, V5, and V6 or a narrow Q wave in lead aVL, in the 
absence of a myocardial pathology, and 4) a peak R time greater than 60 ms in leads V5 and V6 
but normal in leads V1, V2, and V3 when small initial r waves could be discerned in the above 
leads.14) Among the registered study population, 1,168 (20.8%) patients had QRS prolongation 
(>120 ms). Among these population, 292 patients presented with LBBB, 344 patients with 
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intra-ventricular conduction delay (IVCD), 398 patients with RBBB, and 134 with pacing rhythm 
(Figure 1). We included patients with LBBB for analysis in the present study. The Institutional 
Review Board of each hospital approved the study protocol.
Data collection
Detailed information on the study design and results from interim analysis are described in 
our previous paper.15)16) In brief, the investigators completed a web-based case report form at 
enrollment and at each visit in the Clinical Data Management System (iCReaT) from the Korea 
National Institute of Health. The latest information on patient clinical manifestation, laboratory 
results, and medications was collected at admission, at discharge, and during follow-up (30 days, 
3 months, 6 months, and 1 to 5 years annually). In-hospital mortality and the cause of death were 
adjudicated by an independent event committee. The mortality data for patients who were lost to 
follow-up was collected from National Insurance data or National Death Records.
Definitions and outcomes
LAD was defined as a QRS axis <−30 degree in accordance with published criteria.14) 
Echocardiography was available for 96.6% (282/292) of the study population and left 
ventricular ejection fraction (LVEF) was assessed by the biplane Simpson technique, M-mode, 
or visual estimation.17) To evaluate the right ventricle (RV) dilatation on the surface ECG, any 
combination of at least 2 of 3 electrocardiographic criteria (late R in lead aVR, low voltages in 
the limb leads, and R/S ratio <1 in lead V5) was used.18)
The AHFS patients with LBBB were divided into 2 groups according to QRS axis (<−30 or 
≥−30 degree). The primary end point was death from any cause. The secondary end points 
were reduced LVEF and RV dilatation.
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KorAHF registry March 2011–February 2014 
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Figure 1. Study flow. 
AHFS = acute heart failure syndrome; ECG = electrocardiogram; IVCD = intra-ventricular conduction delay; 
KorAHF = Korean Acute Heart Failure; LAD = left axis deviation; LBBB = left bundle branch block; RBBB = right 
bundle branch block.
Statistical analysis
Continuous variables were examined using Student's t-test or Wilcoxon rank-sum test 
when applicable. Categorical data were compared using the χ2 test or Fisher's exact test, as 
appropriate. The event-free survival was assessed by Kaplan-Meier analyses and the significance 
level was evaluated with the log-rank test. In multivariate Cox regression models for the 
survivors, covariates that were suggested to be relevant on univariate analysis with p value <0.2 
or clinically relevant were considered as candidate variables. Adjusted hazard ratios (HRs) 
were compared by Cox regression based on age, sex, ischemic etiology, hypertension, diabetes 
mellitus, LVEF <40%, body mass index ≥25 kg/m2, QRS duration ≥150 ms, and creatinine ≥2 
mg/dL. To assess the association between the QRS axis and echocardiographic parameters, 
including LVEF, E/A ratio, E/e′, deceleration time, left atrial size, and right ventricular systolic 
pressure, a locally weighted scatterplot smoothing (LOESS) method was utilized. To determine 
the predictors of LVEF, a multiple linear regression analysis was used. The variables for analysis 
were selected by the same criteria depicted in the Cox regression model, except LVEF <40%. 
Statistical analyses were performed using R Statistical Software (version 3.1.3; R Foundation for 
Statistical Computing, Vienna, Austria) with a p<0.05 considered statistically significant.
RESULTS
Baseline characteristics of the study population
The median (interquartile range) age of the 292 patients was 75 (68–80) years, and 46.6% 
were males. Patients with de novo HF accounted for 40.8% of the total, and 37.7% of the 
study population were classified as having ischemic cardiomyopathy. Among the study 
population, 80.8% of the patients were in sinus rhythm and 18.5% were in atrial fibrillation 
or flutter. The mean values of QRS duration and LVEF were 155.7 ms and 28.4%, respectively.
Among the study population, 189 (64.7%) patients had a normal axis, and 103 (35.3%) had 
LAD. The baseline clinical characteristics, treatment strategy, laboratory data, and outcomes 
on admission according to the presence of LAD are described in Table 1. Compared to the 
normal axis group, the LAD group had a higher proportion of males and a lower proportion 
of patients with diabetes mellitus. Also, the patients with LAD had a significantly higher 
creatinine level, lower body mass index, and lower LVEF values. The other variables did not 
significantly differ between the 2 groups.
Clinical outcome
The median follow-up duration was 24 months (interquartile range, 12–35). There was a total 
of 123 (42.1%) all-cause deaths during the follow-up period. On univariate analysis, the patients 
with LAD did not have a significantly higher all-cause mortality compared to those with no 
LAD (LAD group vs. no LAD group, 46.6% vs. 39.7%, unadjusted HR, 1.17; 95% confidence 
interval [CI], 0.81, 1.68; p=0.40, Table 2 and Figure 2). Even after adjusting for the clinically 
relevant and statistically significant variables, multivariate analysis did not show any significant 
difference between the 2 groups (adjusted HR, 1.01; 95% CI, 0.66, 1.53; p=0.97, Table 2).
Predictors of the echocardiographic parameters
To determine the impact of the QRS axis on the echocardiographic parameters, an LOESS 
method was performed. The LOESS model results of the echocardiographic parameters are 
depicted in Figure 3. In Figure 3A, the LVEF peaked at 0 degrees of the QRS axis and trended 
downward when the axis was increased or decreased. After dividing the patients into 3 
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Table 1. Baseline clinical characteristics according to the presence of LAD
No LAD (n=189) LAD (n=103) p value
Age (years) 72.6±10.8 74.0±11.7 0.29
Male 79 (41.8) 57 (55.3) 0.04
Alcohol 63 (33.3) 39 (37.9) 0.52
Current smoker 24 (12.7) 14 (13.6) 0.97
Body mass index (kg/m2) 23.5±3.5 22.0±3.5 0.001
Hypertension 105 (55.6) 68 (66.0) 0.11
Diabetes mellitus 89 (47.1) 34 (33.0) 0.03
Chronic kidney disease 26 (13.8) 18 (17.5) 0.50
Cerebrovascular accident 20 (10.6) 17 (16.5) 0.20
Pulmonary disease 20 (10.6) 18 (17.5) 0.14
De-novo heart failure 83 (43.9) 36 (35.0) 0.17
Ischemic etiology 79 (41.8) 31 (30.1) 0.07
NYHA classification 0.24
2 19 (10.1) 17 (16.5)
3 71 (37.6) 39 (37.9)
4 99 (52.4) 47 (45.6)
Systolic blood pressure (mmHg) 127.4±25.5 128.3±27.9 0.80
Heart rate (beats/min) 93.6±21.9 90.4±24.5 0.25
Treatment
Beta blocker at discharge 103 (54.5) 55 (53.4) 0.95
RAS blockade at discharge 138 (73.0) 78 (75.7) 0.72
AA at discharge 105 (55.6) 50 (48.5) 0.31
Mechanical ventilation 30 (15.9) 20 (19.4) 0.55
Laboratory data
QRS axis 21.3±34.8 −49.8±12.3 <0.001
Rhythm 0.50
Sinus rhythm 152 (80.4) 84 (81.6)
Atrial fibrillation 31 (16.4) 18 (17.5)
Miscellaneous 6 (3.2) 1 (1.0)
PR interval (ms) 169.6±38.7 175.5±39.1 0.26
QRS duration (ms) 154.1±17.6 158.3±21.2 0.09
LVEF (%) 29.6±10.0 26.1±9.8 0.006
Na (mg/dL) 137.5±4.7 137.4±4.6 0.77
Creatinine (mg/dL) 1.3±0.8 1.7±1.5 0.01
Outcomes on admission
In-hospital mortality 9 (4.8) 3 (2.9) 0.65
ICU admission 95 (50.3) 52 (50.5) >0.99
Hospital days 9 (6–15) 9 (6–15) 0.89
Data are presented as the mean±standard deviation, number (%) or median (interquartile range).
AA = aldosterone antagonist; ICU = intensive care unit; LAD = left axis deviation; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association;  
PCI = percutaneous coronary intervention; RAS = renin angiotensin system.
Table 2. Multivariate Cox regression analysis for predictors of all-cause mortality
Variables Unadjusted HR (95% CI) p value Adjusted HR* (95% CI) p value
LAD 1.17 (0.81, 1.68) 0.40 1.01 (0.66, 1.53) 0.97
Age 1.04 (1.02, 1.06) <0.001 1.05 (1.02, 1.07) <0.001
Male 1.39 (0.97, 1.98) 0.07 1.36 (0.92, 2.02) 0.12
Ischemic etiology 1.90 (1.33, 2.70) <0.001 1.65 (1.10, 2.48) 0.02
Hypertension 1.30 (0.90, 1.88) 0.16 0.98 (0.65, 1.49) 0.94
Diabetes mellitus 1.10 (0.77, 1.58) 0.59 0.80 (0.53, 1.18) 0.26
LVEF <40% 1.01 (0.60, 1.69) 0.97 1.30 (0.76, 2.22) 0.33
Body mass index ≥25 kg/m2 1.09 (0.72, 1.66) 0.67 1.06 (0.67, 1.67) 0.82
QRS duration ≥150 ms 0.94 (0.65, 1.35) 0.73 0.82 (0.55, 1.22) 0.33
Creatinine ≥2 mg/dL 3.05 (2.05, 4.55) <0.001 3.12 (1.98, 4.93) <0.001
CI = confidence interval; HR = hazard ratio; LAD = left axis deviation; LVEF = left ventricular ejection fraction.
*C-index of the Cox regression model was 0.687 (95% CI, 0.630, 0.744).
groups (QRS axis <−30, −30 to 90, and >90 degree), simple linear regression showed that 
the LAD was a significant predictor of a worse LVEF (adjusted coefficient, −3.03, 95% CI, 
−5.53, −0.52, p=0.02) (Table 3). The significant association between LAD and a worse LVEF 
was maintained on multiple linear regression analysis (adjusted coefficient, −3.25; 95% CI, 
−5.82, −0.67; p=0.01) (Table 3). Although the E/A ratio, LA size, and right ventricular systolic 
pressure appeared to vary as the QRS axis changed, as shown in Figure 3B, 3E, and 3F, there 
was no significant difference among the 3 groups.
RV dilatation
There was a significantly higher proportion of RV dilatation criteria in the LAD group 
compared to the no LAD group (LAD vs. no LAD, 40.8% vs. 12.7%, p<0.001). In particular, a 
late R in aVR was the strongest contributing factor (51.5% vs. 6.3%, p<0.001).
To evaluate the impact of RV dilatation criteria of the surface ECG on all-cause mortality, 
a Kaplan-Meier method with log-rank test was performed. In Figure 4, the Kaplan-Meier 
curve for all-cause death based on RV dilatation criteria showed that there was no significant 
difference in all-cause mortality between the 2 groups (log-rank p=0.751).
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Figure 2. Kaplan-Meier curves of AHFS patients with LBBB according to the presence of LAD. Kaplan-Meier curve 
of all-cause death for AHFS patients with LBBB in the no LAD group (blue line) versus the LAD group (red line). 
AHFS = acute heart failure syndrome; LAD = left axis deviation; LBBB = left bundle branch block.
Table 3. Multiple linear regression analysis for the predictors of lower LVEF
Variables Unadjusted slope (95% CI) p value Adjusted slope (95% CI) p value
Normal QRS axis (reference)
LAD −3.03 (−5.53, −0.52) 0.02 −3.25 (−5.82, −0.67) 0.01
RAD 0.45 (−9.47, 10.36) 0.93 −0.20 (−10.08, 9.67) 0.97
Age 0.18 (0.07, 0.28) 0.001 0.16 (0.04, 0.27) 0.007
Male −1.31 (−3.69, 1.07) 0.28 −0.56 (−3.00, 1.87) 0.65
Ischemic etiology 2.00 (−0.44, 4.44) 0.11 0.69 (−1.88, 3.26) 0.60
Hypertension 2.30 (0.90, 1.88) 0.16 0.98 (0.65, 1.49) 0.94
Diabetes mellitus 2.64 (0.23, 5.06) 0.03 1.57 (−1.08, 4.22) 0.24
Body mass index ≥25 kg/m2 0.98 (−1.83, 3.78) 0.49 0.89 (−1.97, 3.75) 0.54
QRS duration ≥150 ms −0.26 (−2.73, 2.22) 0.84 −0.26 (−2.73, 2.22) 0.83
Creatinine ≥2 mg/dL 1.67 (−1.58, 4.91) 0.31 1.29 (−1.98, 4.57) 0.44
CI = confidence interval; LAD = left axis deviation; LVEF = left ventricular ejection fraction; RAD = right axis deviation.
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Figure 3. LOESS curves of the echocardiographic parameters according to the QRS axis. LOESS curves of the LVEF (A), E/A ratio (B), E/e′ (C), DT (D), LA size (E), 
and RVSP (F) according to the QRS axis. 
DT = deceleration time; LA = left atrium; LOESS = locally weighted scatterplot smoothing; LVEF = left ventricular ejection fraction; RVSP = right ventricular 
systolic pressure.
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Figure 4. Kaplan-Meier curve of all-cause death in AHFS patients with LBBB according to RV dilatation criteria. 
Kaplan-Meier curve of all-cause death in AHFS patients with LBBB in the no RV dilatation group (blue line) versus 
RV dilatation group (red line). 
AHFS = acute heart failure syndrome; LBBB = left bundle branch block; RV = right ventricle.
DISCUSSION
In this study, the prognostic significance of LAD in patients who had AHFS with LBBB was 
investigated using a prospective multicenter cohort registry. There were several main findings 
of our study. 1) Among the AHFS patients with LBBB, the presence of LAD did not predict 
all-cause mortality. 2) The LVEF was significantly lower in AHFS patients with LBBB and LAD 
than in those without LAD. 3) LAD was a significant predictor of RV dilatation, which was 
evaluated by surface ECG criteria in patients with AHFS and LBBB.
The prognostic significance of LAD in patients with LBBB has been controversial in various 
study populations. In chronic LBBB patients, the presence of LAD has been shown to confer 
greater incidence of cardiomegaly, myocardial dysfunction, advanced conduction disease, 
and cardiovascular mortality.11)19) Also, in patients with HF and LBBB who undergo successful 
implantations of CRT devices, the presence of LAD suggests a poor clinical outcome, 
including all-cause mortality and HF re-hospitalizations or events.6)20) Park et al.12) recently 
reported that LAD is associated with myocardial scarring and major adverse cardiac event 
in patients with LBBB. On the other hand, in patients with HF and LBBB who undergo ICD 
implantations, LAD does not predict all-cause mortality or HF events.6) In addition, for LBBB 
patients who undergo an ECG for any reason, LAD does not confer a significant mortality 
risk.13) Our study showed that LAD was not a significant predictor of all-cause mortality in an 
AHFS cohort. To the best of our knowledge, this is the first study to confirm the prognostic 
significance of LAD on clinical outcomes in AHFS patients with LBBB. It was estimated that 
the cause of the discrepancy between our data and the data of HF patients who underwent 
CRT implantations was due to the differences in the study populations and differences in the 
benefit of CRT based on the presence of LAD. Also, we speculated that the prognostic impact 
of LAD had little significance in a high-risk study population, such as those with AHFS and 
LBBB, because they already exhibit multiple poor prognostic factors and mortality risks.
A previous study showed that the presence of LAD in LBBB patients does not signify a further 
decrease in LVEF.21) However, the present study demonstrated that LVEF is significantly lower 
in AHFS patients who have LBBB with LAD than in those without LAD. Also, patients with 
LAD in the present study had a significantly higher proportion of RV dilatation than did 
those without LAD. These results support that the main cause of LAD in patients with LBBB 
is anatomical change, such as cardiomegaly or myocardial scarring resulting from previous 
study.10)22)23) Moreover, lower LVEF seen in the LAD group may be the cause or be a result of 
LAD. Further physiological or pathological studies are needed to evaluate the mechanism of 
LAD in LBBB patients.
Impaired RV function is an established marker of poor prognosis in patients with moderate 
to severe HF.24)25) However, our data showed that the all-cause mortality rate did not 
significantly differ between those who did or did not satisfy the RV dilatation criteria. 
Although numerous studies have been performed to evaluate the impact of RV dysfunction on 
clinical outcomes and CRT benefit, this issue remains controversial.26-28) An additional larger 
prospective cohort study is needed to evaluate the association between RV dysfunction and 
CRT benefit or mortality.
This study had several limitations. First, the current hypothesis was not defined prior to 
conducting the registry, and a relatively small study population was included in the final 
analysis, as the present study population consisted of a subgroup of the KorAHF registry. 
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Second, it was an observational study, which may have affected the results because of 
confounding factors. Third, although the portion of missing data was small, 3.4% of the 
study population did not have echocardiographic data including that of the LVEF. Finally, due 
to the limitations of our data-base, we did not have any information on the RV parameters 
from the echocardiographic data or new onset LAD from the follow-up ECG.
Among AHFS patients with LBBB, the presence of LAD did not predict all-cause mortality, 
but it can be used as a significant predictor of worse LVEF and RV dilatation.
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